InspireMD (NYSE:NSPR) Price Target Lowered to $4.00 at Piper Sandler

InspireMD (NYSE:NSPR) had its price target cut by Piper Sandler from $4.50 to $4.00 in a research note issued to investors on Monday,Benzinga reports. They currently have an overweight rating on the stock.

Separately, StockNews.com began coverage on shares of InspireMD in a research report on Monday, May 5th. They set a “sell” rating on the stock.

InspireMD Stock Down 2.9%

Shares of NYSE NSPR opened at $2.36 on Monday. The firm’s 50-day simple moving average is $2.63 and its 200 day simple moving average is $2.74. The company has a market cap of $72.30 million, a price-to-earnings ratio of -3.15 and a beta of 0.62. InspireMD has a 12-month low of $2.07 and a 12-month high of $3.80.

Institutional Trading of InspireMD

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Uniting Wealth Partners LLC bought a new stake in InspireMD during the 1st quarter worth about $27,000. Renaissance Technologies LLC bought a new stake in shares of InspireMD in the 4th quarter valued at about $27,000. Brown Advisory Inc. bought a new stake in shares of InspireMD in the 1st quarter valued at about $27,000. XTX Topco Ltd bought a new stake in shares of InspireMD in the 1st quarter valued at about $38,000. Finally, Legato Capital Management LLC bought a new stake in shares of InspireMD in the 4th quarter valued at about $47,000. 44.78% of the stock is owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.